Merck KGaA looks for partnership deals to finance drug development

Oct 22, 2018

Merck KGaA could soon be announcing new partnership deals to help finance its promising drug development pipeline. 

According to a report in Reuters, the German drugmaker could specifically use partnerships to continue its development of evobrutinib, an autoimmune disease treatment, and M7842, a cancer medication it is currently testing in comparison to the blockbuster Keytruda. 

Despite the positive results from trials of both medications, Merck is reportedly looking for financing help to offset losses in operating profit from its high-tech chemicals division. 

Both medications have moved into phase 2 trials. 

Read the full Reuters report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments